Chuck,
I agree. The real attraction for a potential partner isn't the chance that bit225 is a blockbuster; the real attraction is that biotron has identified a vulnerability in several viruses , designed a methodology to exploit that vulnerability, and then tested that methodology by developing bit225 and proving its efficacy in clinical trials.
Bit225 is a first-in-class drug.The promise is that biotron's pipeline will produce many more.
Good find vapor!
research article link, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
